Meningitis - Pipeline Analysis and Market Forecasts to 2016

Meningitis - Pipeline Analysis and Market Forecasts to 2016 Summary GlobalData’s report, “Meningitis - Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global meningitis market. The report identifies the key trends shaping and driving the global meningitis market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global meningitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope The scope of the report includes: Annualized global meningitis disease market revenues data from 2006 to 2009, forecast forward for seven years to 2016. Geographic markets covered in this report include the US, Europe and Rest of the World. Pipeline analysis data providing a split across vaccines and drugs. Key vaccine classes include conjugated and recombinant vaccines. Analysis of the current and future market competition in the global meningitis market. Key market players covered are Novartis, GlaxoSmithKline, Sanofi-aventis (Sanofi Pasteur), InterMune and Merck. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessments, market characterization, unmet needs and the implications for the future market associated with meningitis. Reasons to buy The report will enhance your decision making capability. It will allow you to: Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global meningitis market. Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global meningitis market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What’s the next big thing in the global meningitis market landscape? Identify, understand and capitalize.

Additional Information

Meningitis - Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, “Meningitis - Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global meningitis market. The report identifies the key trends shaping and driving the dynamism in the global meningitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global meningitis market.

Meningitis Market is Forecast to Show High Growth Until 2016

GlobalData estimated the global meningitis market to be worth $1.1 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 13.3% to reach $2.7 billion by 2016. This high growth forecast is primarily attributed to the increase in the patient population as a result of the increasing world population, increased disease awareness and wider government immunization recommendations. This growth will be further supported by the increased production capacities of companies to cater for the rising demand. The strong product pipeline will complement the existing products by providing effective options to people.

Global Meningitis Market Forecast, Revenues ($m), 2006-2016

Source: GlobalData

Current Vaccination Options are Highly Successful in Meeting Market Demands

GlobalData found that the products currently in the market are highly efficacious in providing protection against meningitis with minimum side-effects. All the marketed products provide high seroprotection rates and seroconversion rates against the disease. The key products, such as Menactra, ActHIB, Merrem, AmBisome, the Menjugate vaccine and Meningitec vaccine, are able to satisfy the demands of the meningitis market. Despite being highly competitive, the market holds significant opportunities for any new entrants as there is no single vaccine or therapy that is available globally to protect all age groups, and there is untapped market potential for the treatment of the MenACW-135Y and MenB serogroups.

Unmet Need in the Meningitis Market is Low, Mostly Associated with Niche Segments

The meningitis market has very low unmet needs as the market is well served by the current product options. This leaves little scope for new entrants to capture value from under-served segments. The new products have to aim at gaining market share by providing unique offerings and targeting niche segments. The likely under-served segments are those people suffering with the MenACW-135Y and MenB serogroups. The current pipeline, however, is strong enough to cater for this unmet need.

Meningitis Market - Opportunity and Unmet Need, 2010

Source: GlobalData

Strong Pipeline Candidates Will Encourage Competition in the Meningitis Market

GlobalData found that the product pipeline for meningitis is strong, with 35 molecules in various phases of clinical development. There are 10 molecules in phase III, 11 in phase II and 12 molecules undergoing phase I clinical trials. A large portion of these are vaccines are more safe and efficacious than the currently marketed products, with novel development procedures or routes of administration. They target the small unmet need that exists in the market. They will compete with the well established vaccines and are likely to redefine the competitive landscape in the market.

Competitive Landscape in the Meningitis Market Will be Driven by Pricing and First-To-Market Strategy

GlobalData predicts that Novartis, GlaxoSmithKline (GSK), Sanofi-aventis (Sanofi Pasteur), InterMune and Merck will remain as the leading competitors in the global meningitis market. New entrants into the market will have to compete mostly on the pricing of their products as the unmet need in the market is quite low. Another strategy for the industry is the first-to-market strategy. The safety and efficacy of the vaccines are similar; hence, the vaccine first to enter the market is likely to gain the maximum market share. With a few points to compete on, the competition in the meningitis market is likely to increase in the future.